TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
TESARO an oncology-focused biopharmaceutical company, announced that following the recent identification of a fixed dose and patient-centric dosing schedule, the ongoing clinical trial…
Read More...
Read More...
